Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742281 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
A Phase 2 study of COVID-19, sponsored by CyanVac.
- Active
- Registry status
- Phase 2
- Development phase
- 432
- Enrollment target
- 20
- Study locations
NCT06742281: Active Phase 2 study of COVID-19, sponsored by CyanVac.
NCT06742281 is a Phase 2 study of COVID-19 that is active but no longer recruiting, run by CyanVac. The registered enrollment target is 432 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06742281, a Phase 2 study of COVID-19, is active but no longer recruiting, sponsored by CyanVac.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 432 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 434 healthy participants.
Primary Outcome
First occurrence of molecularly confirmed (RT-PCR-positive) symptomatic COVID-19 according to the case definition with onset at least 14 days post-vaccination through 12 months post-vaccination. Case definition: Virologically confirmed SARS-CoV-2 infection (by RT-PCR) with 1 or more of the following symptoms within ±7 days: * Fever or chills * Cough * Shortness of breath or difficulty breathing * Fatigue * Muscle or body aches * Headache * New loss of taste or smell * Sore throat * Congestion
Conditions Studied
Interventions
- BIOLOGICAL CVXGA (CVXGA50)
- BIOLOGICAL COMIRNATY®
Study Locations (20)
California
- Velocity Clinical Research, Chula Vista - Chula Vista
- Velocity Clinical Research, San Diego - La Mesa
- Imax Clinical Trials - La Palma
- Artemis Institute for Clinical Research - Riverside
- Clinical Innovations Inc. dba CITrials - Riverside
- Avacare - Sacramento
- Collaborative Neuroscience Research, LLC - Torrance
Florida
- Velocity Clinical Research, Hallandale Beach - Hallandale
- Homestead Associates in Research, Inc - Homestead
- Biscayne Clinical Research - North Miami Beach
- Headlands Research Orlando - Orlando
- Best Choice Medical and Research Service - Pembroke Pines
- Forcare Clinical Research - Tampa
- Guardian Angel Research Center - Tampa
Georgia
- Lifeline Primary Care/Avacare - Lilburn
- Velocity Clinical Research, Savannah - Savannah
- Clinical Research Atlanta - Stockbridge
Alabama
- Pinnacle Research Group, LLC - Anniston
Arizona
- Velocity Clinical Research, Phoenix - Phoenix
District of Columbia
- Velocity Clinical Research, Washington DC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What the registry record for NCT06742281 still lists
NCT06742281 is an interventional study that assigns participants to a tested intervention. The registered 432 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which CVXGA (CVXGA50) is the first listed.
NCT06742281 names 20 study sites across 6 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06742281 about?
NCT06742281 is a clinical study titled "A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults". The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. Th...
What is the current status of trial NCT06742281?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 432 participants. The study started on 2024-12-05. Estimated completion is 2027-06.
What conditions does trial NCT06742281 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06742281?
The interventions under investigation include: CVXGA (CVXGA50) (BIOLOGICAL), COMIRNATY® (BIOLOGICAL).
Who is sponsoring clinical trial NCT06742281?
This trial is sponsored by CyanVac, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06742281 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06742281's enrollment target sits among peer trials
432 120th of 298 higher than 179 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
- NCT05806164 · 432 participants · Phase 4
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI